QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
OTCMKTS:NICXF

Nicox (NICXF) Stock Price, News & Analysis

$0.44
0.00 (0.00%)
(As of 04/18/2024 ET)
Today's Range
$0.44
$0.44
50-Day Range
$0.44
$0.44
52-Week Range
$0.44
$0.44
Volume
N/A
Average Volume
N/A
Market Capitalization
$22.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NICXF stock logo

About Nicox Stock (OTCMKTS:NICXF)

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.

NICXF Stock Price History

NICXF Stock News Headlines

Forget NVIDIA, buy this $2 AI stock now…
This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.
Forget NVIDIA, buy this $2 AI stock now…
This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.
Nicox S.A. (ALCOX.PA)
Nicox SA Share from reverse split ALCOX
10 Best Pokémon Anime Openings, Ranked
Nicox reports Q3 results
See More Headlines
Receive NICXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nicox and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:NICXF
Previous Symbol
NASDAQ:NICXF
CIK
N/A
Employees
28
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.52 million
Book Value
$1.10 per share

Miscellaneous

Free Float
N/A
Market Cap
$22.04 million
Optionable
Not Optionable
Beta
0.36
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Michele Garufi Ph.D. (Age 70)
    Co-Founder & Director
    Comp: $471.16k
  • Dr. Gavin M. Spencer (Age 54)
    Chief Executive Officer
  • Ms. Sandrine Gestin (Age 57)
    Vice President of Finance
  • Mr. Doug Hubatsch (Age 57)
    Executive VP & Chief Scientific Officer
  • Dr. Ramesh Krishnamoorthy
    Senior Director and Head of Late Stage CMC & Quality Control
  • Dr. Jose Boyer
    Consultant

NICXF Stock Analysis - Frequently Asked Questions

How have NICXF shares performed in 2024?

Nicox's stock was trading at $0.44 at the beginning of the year. Since then, NICXF shares have increased by 0.0% and is now trading at $0.44.
View the best growth stocks for 2024 here
.

How do I buy shares of Nicox?

Shares of NICXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NICXF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners